NASDAQ:CELG - Celgene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$86.35 -0.24 (-0.28 %)
(As of 01/18/2019 03:38 PM ET)
Previous Close$86.59
Today's Range$85.87 - $86.95
52-Week Range$58.59 - $106.67
Volume553,956 shs
Average Volume14.08 million shs
Market Capitalization$61.04 billion
P/E Ratio12.60
Dividend YieldN/A
Beta1.44
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaboration with Skyhawk Therapeutics, Inc. and Dragonfly Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.00 billion
Cash Flow$7.5349 per share
Book Value$8.79 per share

Profitability

Net Income$2.94 billion

Miscellaneous

Employees7,467
Market Cap$61.04 billion
OptionableOptionable

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Shares of Celgene split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were payable to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene announced that its board has approved a share repurchase plan on Thursday, May 24th 2018, which permits the company to buyback $3,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 5.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's management believes its shares are undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) released its quarterly earnings data on Thursday, October, 25th. The biopharmaceutical company reported $2.29 EPS for the quarter, beating the Zacks' consensus estimate of $2.02 by $0.27. The biopharmaceutical company earned $3.89 billion during the quarter, compared to analyst estimates of $3.83 billion. Celgene had a net margin of 19.64% and a return on equity of 108.76%. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene issued an update on its FY19 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of $10.60-10.80 for the period, compared to the Thomson Reuters consensus estimate of $10.32. The company issued revenue guidance of $17-17.2 billion, compared to the consensus revenue estimate of $16.93 billion.Celgene also updated its FY 2018 guidance to $8.75-8.80 EPS.

What price target have analysts set for CELG?

25 Wall Street analysts have issued 1-year price objectives for Celgene's shares. Their forecasts range from $77.00 to $150.00. On average, they anticipate Celgene's stock price to reach $107.4737 in the next twelve months. This suggests a possible upside of 24.0% from the stock's current price. View Analyst Price Targets for Celgene.

What is the consensus analysts' recommendation for Celgene?

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 10 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. Cantor Fitzgerald analysts commented, "We think Celgene remains a show-me story to investors, which has the stock trading at a discount to peers. We are cautiously optimistic with management changes that execution is improving. We think that the base business remains strong for 2019, and we think filing key late-stage programs over 2019 will help get the stock back on track. The company has many late-stage programs like liso-cel, luspatercept, ozanimod in MS. bb2121 that could launch in late 19/early 2020. Valuation Summary We have a $100 PT on the shares." (1/3/2019)
  • 2. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid, continues to drive revenues at the company. Celgene is also currently working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla among others, which is encouraging. Meanwhile, the company is focussed on the next cycle of innovation with five late-stage candidates — ozanimod, fedratinib, luspatercept, liso-cel and bb2121 — all of which are expected to be launched by the end of 2020. Celgene acquired Juno Therapeutics and added JCAR017 to its lymphoma pipeline to revive its portfolio. Luspatercept looks promising as well with positive data from two late-stage trials. However, shares have underperformed the industry in the year so far. The company’s dependence on Revlimid sales is a concern as well. Celgene suffered a setback when it received a Refusal to File letter from the FDA, regarding the NDA for ozanimod in relapsing multiple sclerosis." (12/31/2018)
  • 3. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call. Here are the key changes we made: ===Upward Revisions=== 1. bb2121. Added bb2121 to pipeline section of the model ($1Bn in risk- adjusted peak sales to CELG vs consensus of $900MM) 2. Luspatercept. Increased POS from 67% to 90% on the back of the recent positive Ph 3 results. (peak risk-adj sales now of $1Bn, ex-royalty to XLRN …. consensus at $850MM) ===Downward Revisions=== 3. Ozanimod MS. Trimmed peak risked adjusted sales from $1.3Bn to $1.1Bn. In total, across all 3 indications (MS, UC, CD), we carry $2.8Bn (vs consensus of $2.5Bn)." (7/31/2018)
  • 4. Cowen Inc analysts commented, "We will be hosting a conference call with neurologist to discuss and TD-9855. Theravance is evaluating 1/2 trial in patients with . Results are expected to be available this month." (7/10/2018)
  • 5. Canaccord Genuity analysts commented, "We expect median Progression Free Survival (PFS) > 10 months for the initial bb2121 dose escalation cohort previously reported at ASH 2017, based on 71% progression free at 9 months. Importantly, we believe PFS data could easily exceed our estimate and the 8.8 months PFS seen for pomalidomide + daratumumab + dexamethasone in Phase 1b. Duration of follow-up key for new n=21 patient cohort Investors should carefully consider the median follow-up time for the new n=21 patient bb2121 cohort with no BCMA expression cutoff, since Complete Responses improve over time. We will consider the initial bb2121 data presented at AACR in 2016, where a 78% ORR and 22% CR rate was seen. Importantly, we expect a very rapid Overall Response Rate, as seen for initial bb2121 data." (5/30/2018)

Has Celgene been receiving favorable news coverage?

News stories about CELG stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celgene earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 59)
  • Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 62)
  • Dr. S. J. Rupert Vessey, Pres of Research & Early Devel. (Age 53)
  • Mr. David V. Elkins, Exec. VP & CFO
  • Mr. Aijaz Tobaccowalla, Sr. VP and Chief Digital & Information Officer (Age 51)

Who are Celgene's major shareholders?

Celgene's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Factory Mutual Insurance Co. (0.12%), Douglas Lane & Associates LLC (0.12%), LGT Capital Partners LTD. (0.10%), Gateway Investment Advisers LLC (0.07%), Gofen & Glossberg LLC IL (0.06%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own Celgene stock include Ernest Mario, Gilla Kaplan, James J Loughlin, John H Weiland, Mark J Alles, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which institutional investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Cullinan Associates Inc., Nisa Investment Advisors LLC, Highland Capital Management LLC, Patten & Patten Inc. TN, Gibraltar Capital Management Inc., Capital Investment Services of America Inc. and Personal Capital Advisors Corp. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin and Michael D Casey. View Insider Buying and Selling for Celgene.

Which institutional investors are buying Celgene stock?

CELG stock was acquired by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., LGT Capital Partners LTD., DNB Asset Management AS, Bowling Portfolio Management LLC, Douglas Lane & Associates LLC, Virtu Financial LLC, Penn Davis Mcfarland Inc. and Boston Advisors LLC. Company insiders that have bought Celgene stock in the last two years include John H Weiland and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $86.70.

How big of a company is Celgene?

Celgene has a market capitalization of $61.04 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $6.84 on an earnings per share basis. Celgene employs 7,467 workers across the globe.

What is Celgene's official website?

The official website for Celgene is http://www.celgene.com.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]


MarketBeat Community Rating for Celgene (NASDAQ CELG)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  1,924 (Vote Outperform)
Underperform Votes:  682 (Vote Underperform)
Total Votes:  2,606
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel